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ABSTRACT
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a newer 
class of Type 2 diabetes medications. The drugs are rapidly growing 
in popularity. In the period between October 2014 and September 
2015, doctors wrote 1.5 million prescriptions for Invokana or Farxiga 
(dapagliflozin), according to the FDA. They also come in extended 
formulas and in formulas combined with metformin. These drugs 
work by preventing the kidneys from reabsorbing sugar and 
releasing it into the blood. But, what makes these medications so 
effective, could also contribute to a number of side effects. Beginning 
in December 2015, the FDA released a number of warnings linking 
these drugs to a number of side effects, some can be fatal.  These 
range from common ones like yeast infections to more dangerous, 
rare problems like a link to increased bladder cancer risk and diabetic 
ketoacidosis
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INTRODUCTION
Sodium-glucose co-transporter 2 (SGLT2) inhibi-
tors are a newer class of Type 2 diabetes medications. 
The first drug in this class was Invokana (canagli-
flozin), first approved in 2013. After Invokana, a 
number of other SGLT2 inhibitors hit the market. 
Studies show they are effective in controlling excess 
blood glucose and lowering A1C in people with 
Type 2 diabetes.
The drugs are rapidly growing in popularity. In 
the period between October 2014 and September 
2015, doctors wrote 1.5 million prescriptions for 
Invokana or Farxiga (dapagliflozin), according to 
the FDA. They also come in extended formulas and 
in formulas combined with metformin.
These drugs work by preventing the kidneys 
from reabsorbing sugar and releasing it into the 
blood. But, what makes these medications so 
effective, could also contribute to a number of 
side effects. Beginning in December 2015, the 
FDA released a number of warnings linking these 
drugs to a number of side effects, some can be 
fatal.  These range from common ones like yeast 
infections to more dangerous, rare problems like a 
link to increased bladder cancer risk and diabetic 
 ketoacidosis—too much acid in the blood.1,2
Invokana is the most popular medication in 
this class, but there are four other FDA-approved 
SGLT2 inhibitors on the market. As FDA warnings 
continue to stack up against these drugs, SGLT2 
lawyers are filing lawsuits on behalf of patients 
who say they suffered severe side effects from these 
drugs. Plaintiff say drug companies failed to warn 
them about the risks.3
The mechanisms
Sodium-glucose co-transporter-2 inhibitors work 
by inhibiting SGLT2 in the PCT, to prevent reab-
sorption of glucose and facilitate its excretion in 
urine. As glucose is excreted, its plasma levels 
fall leading to an improvement in all glycemic 
parameters.4-6
This mechanism of action is dependent on 
blood glucose levels and, unlike the actions of 
thiazolidinediones (mediated through GLUTs), is 
independent of the actions of insulin. Thus, there 
is minimal potential for hypoglycemia, and no 
risk of overstimulation or fatigue of the beta cells.7 
Because their mode of action relies upon normal 
renal glomerular-tubular function, SGLT2i efficacy 
is reduced in persons with renal impairment.
Side effects
Nvokana’s side effects range from yeast infections 
to more serious issues like diabetic ketoacidosis. In 
May 2015 the FDA issued a drug safety communi-
cation that warned patients and doctors that studies 
linked Invokana and Invokamet — and other SGLT2 
inhibitors — to diabetic ketoacidosis (DKA).
Unlike other SGLT2’s, the FDA also found a 
link between Invokana and increased toe and foot 
amputations. The agency released a Drug Safety 
Communication in May 2016 and said it was inves-
tigating. Additionally, Invokana was not tested in 
pregnant women, but animal studies showed irre-
versible kidney problems in fetuses.
Despite the effectiveness of Invokana, it also has 
a notable list of side effects — some of which led 
plaintiffs to file lawsuits.
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According to Janssen’s news release, “Invokana 
is generally well tolerated, and the most common 
adverse events include genital yeast infection, 
urinary tract infections and changes in urination. 
The most common adverse reactions due to initi-
ation of metformin, as noted in the prescribing 
information for that medication, are diarrhea, 
nausea, vomiting, flatulence, asthenia, indigestion, 
abdominal discomfort, and headache.”
But, the FDA released several safety communica-
tions warning the public about a number of serious 
adverse event reports. The first came in May 2015, 
just two years after the drug’s approval. The FDA 
warned Invokana and other SGLT2 inhibitors could 
increase the risk of diabetic ketoacidosis (DKA) — 
a condition where too many toxins called ketones 
develop in the blood. DKA is a serious condition 
that requires hospitalization and may lead to coma 
or death.
Later that year, the agency released two more 
warnings linked to Invokana for increased 
bone-fracture risk and serious urinary tract infec-
tions. These infections could lead to blood and 
kidney infections, the FDA warned. Then, in 2016, 
the agency strengthened the kidney damage warn-
ing for Invokana and another SGLT2 drug, Farxiga8 
(table 1).
In 2016, the FDA also began investigating 
reports of acute pancreatitis linked to SGLT2 inhib-
itors. Acute pancreatitis occurs when the pancreas, 
the organ responsible for producing insulin, 
becomes swollen and inflamed. It can cause serious 
health issues if not treated and may even be fatal. 
Currently, the agency is “evaluating the need for 
regulatory action.”
Invokana is available in 100 mg and 300 mg 
tablets. People with moderate renal problems 
should not take more than 100 mg daily, and 
doctors do not recommend Invokana for people 
with poor kidney function. Some side effects were 
more severe with higher doses.
CONCLUDING REMARKS
Though SGLT2 inhibitors represent a novel class 
of drugs which will certainly help a large number 
of people with diabetes achieve target control in a 
safe and well-tolerated manner, they pose serious 
life threatening side effects in certain population 
of diabetics. Only long term studies and further 
post-marketing surveillance will decide the fact 
that these class of medications will be a sustainable 
antidiabetics like metformin or sulfonylureas. Their 
unique mechanism of action, coupled with pleiotro-
pic benefits on weight and blood pressure, should 
make them attractive choices for add-on therapy to 
persons not controlled on other medications.
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Table 1 Side effects of SGLT2 inhibitiors8
Urinary tract infections Increased urination Thirst
Dry mouth Male and female yeast infections Constipation
Nausea Abdominal pain Fatigue
Loss of strength or energy Hypersensitivity (rash, swelling) Hypoglycemia
Diabetic ketoacidosis 
(DKA)
